Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

AxoGen (AXGN) closed the last trading session at $12.35, gaining 32.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $15.50 indicates a 25.5% upside potential.The average comprises six short-term price targets ranging from a low of $12 to a high of $20, with a standard deviation of $2.74. While the lowest estimate indicates a decline of 2.8% from the current price level, the most ...

Have you been paying attention to shares of AxoGen (AXGN) ? Shares have been on the move with the stock up 28.6% over the past month. The stock hit a new 52-week high of $11.76 in the previous session. AxoGen has gained 71.7% since the start of the year compared to the 9.5% move for the Zacks Medical sector and the 7.6% return for the Zacks Medical - Instruments industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings cons ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to______________ Commission file number: 001-36046 Axogen, Inc. (Exa ...

AxoGen, Inc. (NASDAQ:AXGN) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Harold Tamayo - Vice President-Finance and Investor Relations Karen Zaderej - Chairman, Chief Executive Officer and President Nir Naor - Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Sarcone - Jefferies Catlin Cronin - Canaccord Genuity Jayson Bedford - Raymond James Dave Turkaly - Citizens JMP Operator Greetings, and welcome to the AxoGen, Inc. Reports ...

AxoGen (AXGN) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 200%. A quarter ago, it was expected that this regenerative medicine company would post a loss of $0.10 per share when it actually produced a loss of $0.06, delivering a surprise of 40%.Over the last four quarters, th ...

Axogen, Inc Reports Second Quarter 2024 Financial Results ALACHUA and TAMPA, FL – August 8, 2024 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quarter ended June 30, 2024. Second Quarter Financial Results • Second quarter revenue was $47.9 million, a 25.6% increase compared to the second quarter of 2023. • In the second quarter of 2024, our gross m ...

AxoGen (AXGN) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on August 8. On the o ...

ALACHUA and TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may d ...

AxoGen (AXGN) shares ended the last trading session 8.2% higher at $8.33. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 4.5% loss over the past four weeks.Axogen scored a strong price increase, driven by the optimism surrounding the launch of its latest nerve protection solution, Avive+ Soft Tissue Matrix, last month. Besides, the company is expected to release its second-quarter 2024 results in August. In the fi ...